Experimental Study of Yeast RNA Preparation as a Possible Radioprotective Agent for Radiotherapy of Malignant Tumors

• Published in: Bulletin of experimental biology and medicine 2017-09, Vol.163 (5), p.639-642
• Main Authors: Nikolin, V. P., Bogachev, S. S., Popova, N. A., Tornuev, Yu. V., Vinogradova, E. V.
• Format: Article
• Language: English
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Cancer metastasis; Cell Biology; Dose-Response Relationship, Radiation; Drug therapy; Health aspects; Internal Medicine; Ionizing radiation; Laboratory Medicine; Leukemia; Leukemia - drug therapy; Leukemia - genetics; Leukemia - therapy; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - therapy; Male; Mice; Neoplasm Metastasis - drug therapy; Neoplasm Metastasis - genetics; Neoplasm Metastasis - therapy; Pathology; Radiation-Protective Agents - therapeutic use; Radiotherapy; RNA; RNA, Fungal - genetics; Saccharomyces cerevisiae - genetics
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-017-3868-x

We studied radioprotective effects of a preparation based on yeast RNA and its influence on therapeutic efficiency of ionizing radiation against transplanted tumors. Parenteral administration of yeast RNA preparation to mice in a dose of 10 mg 1 h prior to exposure to ionizing γ-radiation ( 137 Cs) in a lethal dose (LD 80/30 ) increased 30-day survival by 66%; by day 80, 80% of animals survived ( vs . 2.5% in the control). Whole-body exposure to ionizing γ-radiation in a dose of 7 Gy significantly increased the mean lifespan of mice with experimental lung metastases or intraperitoneally transplanted leukemia L-1210 by 42 and 20.8%, respectively. RNA preparation injected to the mice with tumors 1 h before irradiation did not affect the therapeutic efficiency of ionizing radiation or significantly potentiated it (in mice with transplanted leukemia L-1210). These results suggest that yeast RNA preparation protects healthy tissues during radiotherapy of malignant tumors.